Treatment of hepatitis C in potential kidney and heart transplant patients

Fabrizio Fabrizi, Suphamai Bunnapradist, Paul Martin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The recent availability of effective antiviral agents offers new options in the management of chronic hepatitis C in infected organ transplant candidates. The use of IFN after renal transplantation for HCV-infected recipients is complicated by the high rate of graft impairment. IFN monotherapy can lead to excellent results in selected patients on dialysis, with long-term remission being durable after RT. Preliminary data encourage the cautious use of combined therapy (IFN plus RBV) in dialysis populations. The use of PEGIFN monotherapy in dialysis patients is under evaluation. The frequency and outcome of HCV infection after orthotopic heart transplant remains poorly characterized. The limited information on antiviral therapy for HCV infection in orthotopic heart recipients suggests that IFN can be safely administered and is well tolerated. No data on antiviral therapy in heart transplant candidates exist. Large-scale trials are necessary to assess the optimal antiviral regimen. More data are needed on the role of liver biopsy in assessing the risk of organ transplant in cardiac and renal transplant candidates with HCV.

Original languageEnglish
Pages (from-to)487-503
Number of pages17
JournalClinics in Liver Disease
Volume9
Issue number3
DOIs
StatePublished - Aug 1 2005
Externally publishedYes

Fingerprint

Hepatitis C
Transplants
Kidney
Antiviral Agents
Dialysis
Therapeutics
Chronic Hepatitis C
Infection
Kidney Transplantation
Biopsy
Liver
Population

ASJC Scopus subject areas

  • Hepatology

Cite this

Treatment of hepatitis C in potential kidney and heart transplant patients. / Fabrizi, Fabrizio; Bunnapradist, Suphamai; Martin, Paul.

In: Clinics in Liver Disease, Vol. 9, No. 3, 01.08.2005, p. 487-503.

Research output: Contribution to journalArticle

Fabrizi, Fabrizio ; Bunnapradist, Suphamai ; Martin, Paul. / Treatment of hepatitis C in potential kidney and heart transplant patients. In: Clinics in Liver Disease. 2005 ; Vol. 9, No. 3. pp. 487-503.
@article{ac6545e239b84e8284fec2d6d6ff2d92,
title = "Treatment of hepatitis C in potential kidney and heart transplant patients",
abstract = "The recent availability of effective antiviral agents offers new options in the management of chronic hepatitis C in infected organ transplant candidates. The use of IFN after renal transplantation for HCV-infected recipients is complicated by the high rate of graft impairment. IFN monotherapy can lead to excellent results in selected patients on dialysis, with long-term remission being durable after RT. Preliminary data encourage the cautious use of combined therapy (IFN plus RBV) in dialysis populations. The use of PEGIFN monotherapy in dialysis patients is under evaluation. The frequency and outcome of HCV infection after orthotopic heart transplant remains poorly characterized. The limited information on antiviral therapy for HCV infection in orthotopic heart recipients suggests that IFN can be safely administered and is well tolerated. No data on antiviral therapy in heart transplant candidates exist. Large-scale trials are necessary to assess the optimal antiviral regimen. More data are needed on the role of liver biopsy in assessing the risk of organ transplant in cardiac and renal transplant candidates with HCV.",
author = "Fabrizio Fabrizi and Suphamai Bunnapradist and Paul Martin",
year = "2005",
month = "8",
day = "1",
doi = "10.1016/j.cld.2005.05.006",
language = "English",
volume = "9",
pages = "487--503",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Treatment of hepatitis C in potential kidney and heart transplant patients

AU - Fabrizi, Fabrizio

AU - Bunnapradist, Suphamai

AU - Martin, Paul

PY - 2005/8/1

Y1 - 2005/8/1

N2 - The recent availability of effective antiviral agents offers new options in the management of chronic hepatitis C in infected organ transplant candidates. The use of IFN after renal transplantation for HCV-infected recipients is complicated by the high rate of graft impairment. IFN monotherapy can lead to excellent results in selected patients on dialysis, with long-term remission being durable after RT. Preliminary data encourage the cautious use of combined therapy (IFN plus RBV) in dialysis populations. The use of PEGIFN monotherapy in dialysis patients is under evaluation. The frequency and outcome of HCV infection after orthotopic heart transplant remains poorly characterized. The limited information on antiviral therapy for HCV infection in orthotopic heart recipients suggests that IFN can be safely administered and is well tolerated. No data on antiviral therapy in heart transplant candidates exist. Large-scale trials are necessary to assess the optimal antiviral regimen. More data are needed on the role of liver biopsy in assessing the risk of organ transplant in cardiac and renal transplant candidates with HCV.

AB - The recent availability of effective antiviral agents offers new options in the management of chronic hepatitis C in infected organ transplant candidates. The use of IFN after renal transplantation for HCV-infected recipients is complicated by the high rate of graft impairment. IFN monotherapy can lead to excellent results in selected patients on dialysis, with long-term remission being durable after RT. Preliminary data encourage the cautious use of combined therapy (IFN plus RBV) in dialysis populations. The use of PEGIFN monotherapy in dialysis patients is under evaluation. The frequency and outcome of HCV infection after orthotopic heart transplant remains poorly characterized. The limited information on antiviral therapy for HCV infection in orthotopic heart recipients suggests that IFN can be safely administered and is well tolerated. No data on antiviral therapy in heart transplant candidates exist. Large-scale trials are necessary to assess the optimal antiviral regimen. More data are needed on the role of liver biopsy in assessing the risk of organ transplant in cardiac and renal transplant candidates with HCV.

UR - http://www.scopus.com/inward/record.url?scp=22044435954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22044435954&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2005.05.006

DO - 10.1016/j.cld.2005.05.006

M3 - Article

VL - 9

SP - 487

EP - 503

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -